Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial

IMPORTANCE: There is a critical need for careful and independent validation of reported symptomatic efficacy and dopaminergic biomarker changes induced by nilotinib in Parkinson disease (PD). OBJECTIVES: To assess safety and tolerability of nilotinib in participants with moderately advanced PD. Seco...

Descripción completa

Detalles Bibliográficos
Autores principales: Simuni, Tanya, Fiske, Brian, Merchant, Kalpana, Coffey, Christopher S., Klingner, Elizabeth, Caspell-Garcia, Chelsea, Lafontant, David-Erick, Matthews, Helen, Wyse, Richard K., Brundin, Patrik, Simon, David K., Schwarzschild, Michael, Weiner, David, Adams, Jamie, Venuto, Charles, Dawson, Ted M., Baker, Liana, Kostrzebski, Melissa, Ward, Tina, Rafaloff, Gary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737147/
https://www.ncbi.nlm.nih.gov/pubmed/33315105
http://dx.doi.org/10.1001/jamaneurol.2020.4725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7737147/
https://www.ncbi.nlm.nih.gov/pubmed/33315105
http://dx.doi.org/10.1001/jamaneurol.2020.4725

Ejemplares similares